All Immunology articles
-
NewsPim1 kinase identified as therapeutic target for inflammatory arthritis
Researchers have identified Pim1 kinase as a critical driver of inflammatory arthritis through its regulation of Th17 cell differentiation via mitochondrial metabolism.
-
ArticleFlow-based human tumour models reveal immune responses missed by static culture
Static cultures may not tell the whole story when it comes to immunotherapy performance. Results from the Mera™ flow-based human tissue model show stronger T-cell activity and cytokine responses under physiological flow, highlighting the role of dynamic immune–tumour interactions in preclinical testing.
-
ArticlePomegranate-derived compound shows therapeutic potential in heart disease
Researchers at Cardiff University have identified urolithin A – a compound produced by gut bacteria during the metabolism of substances found in pomegranates – as a potential new approach for treating cardiovascular disease.
-
NewsMineralised DNA hydrogel accelerates bone repair in preclinical studies
A mineralised DNA hydrogel has demonstrated accelerated bone repair and improved tissue mineralisation in preclinical studies, offering a potential new approach to treating difficult bone defects through combined immune regulation and sustained regeneration.
-
NewsCytokine-armoured CAR T cells target glioblastoma while reducing treatment toxicity
UCLA Health researchers have developed cytokine-armoured CAR T cells that directly attack glioblastoma tumours whilst recruiting the body’s wider immune system. The engineered cells showed improved tumour control in mouse models and could address antigen heterogeneity challenges that have limited CAR T therapy success in solid tumours.
-
NewsRadiotherapy boosts CAR T cell survival in solid tumours
Mount Sinai researchers have discovered that focused irradiation significantly enhances CAR T cell therapy effectiveness in solid tumours by promoting dendritic cell-mediated antigen presentation, enabling sustained immune cell expansion within the tumour microenvironment whilst minimising off-target toxicity.
-
NewsNotch2 enables breast cancer dormancy in protective bone marrow niches
New research has demonstrated how breast cancer cells exploit protective bone marrow niches to remain dormant for years, identifying Notch2 signalling and stem cell-like markers as key regulators of cellular dormancy that could inform therapeutic strategies to prevent relapse.
-
NewsGene-based CIN score predicts breast cancer survival and immunotherapy response
A 13-gene chromosomal instability scoring system developed by Shanghai researchers correlates with survival outcomes and immunotherapy response in breast cancer patients.
-
NewsPlatinum-antibody conjugates enhance immunotherapy while reducing chemotherapy toxicity
A novel platinum(IV)-antibody conjugate platform delivers low-dose chemotherapy directly to tumours, upregulating MHC-I expression and enhancing anti-PD-1 responses while minimising systemic exposure. The approach addresses immune evasion mechanisms that limit checkpoint inhibitor efficacy.
-
NewsStudy reveals how GLP-1 drugs trigger weight loss in brain cells
NIH researchers have identified the intracellular signalling pathways through which semaglutide and other GLP-1 receptor agonists induce weight loss, revealing why patient responses vary and treatment effects plateau over time.
-
ArticleWhen antibiotics are not enough: the case for immune-engaging therapies
As antimicrobial resistance grows and patient populations become more complex, the limitations of antibiotics are becoming harder to ignore. Dr Helen Bright, CSO at Centauri Therapeutics, discusses a new approach that targets both the pathogen and the host.
-
NewsRAGE receptor identified as key driver of age-related metastasis
Georgetown Lombardi researchers have identified RAGE, an inflammatory receptor, as a key mediator of age-related breast cancer metastasis.
-
NewsMitochondrial fission activation offers new tool in fight against antibiotic resistance
Scientists at The University of Queensland have discovered that activating mitochondrial fission can enhance immune defences against antibiotic-resistant bacteria.
-
NewsCD4+ T cells identified as key to hepatitis B clearance
University of California, San Francisco researchers have identified a crucial immune mechanism involving CD4+ T cells that explains why some chronic hepatitis B patients successfully clear the virus after stopping antiviral treatment.
-
NewsNew framework evaluates AI reliability in immune system prediction
Researchers at the University of South Florida have developed a comprehensive framework to test how accurately AI systems can predict immune responses, addressing critical questions about the reliability of computational tools in drug discovery.
-
NewsNew dual-action drug candidate extends survival in pancreatic cancer models
Researchers have developed a dual-mechanism compound that significantly extended survival in preclinical pancreatic cancer models by simultaneously activating immune responses and blocking suppressive pathways.
-
NewsNew imaging reveals how immune cells destroy cancer
Cryo-expansion microscopy has enabled researchers to visualise the three-dimensional organisation of cytotoxic T lymphocytes destroying cancer cells in their near-native state, revealing nanoscale structural details of the immune synapse and cytotoxic granules that could refine immuno-oncology therapeutic strategies.
-
NewsRepurposed cancer drugs target root cause of Crohn’s Disease
Researchers at the University of Houston have identified epithelial stress signalling as a key driver of Crohn’s disease and demonstrated that two FDA-approved cancer drugs can interrupt the pathological cycle of cell death and inflammation.
-
NewsNew immune mapping reveals lung tumour microenvironment dynamics
VIB-VUB researchers have developed a patient-relevant lung adenocarcinoma model combined with SEPARATE-Seq technology to create detailed immune maps distinguishing tissue-infiltrating cells from circulating populations.
-
NewsOsteoporosis drugs may slow progression of aortic aneurysms
Researchers at Nagoya University have identified clonal haematopoiesis as a driver of aortic aneurysm progression and demonstrated that FDA-approved osteoporosis therapies targeting the RANK/RANKL pathway can significantly slow disease progression in preclinical models.